Powered by

CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan

Aug 05, 2019 - PR Newswire

PR Newswire

 CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using itsCytoSorb®blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces it has received an additional $5 million in cash through an amended loan agreement with Bridge Bank's Life Sciences Group.

On July 31, 2019 (the Settlement Date"), the Company entered into the First Amendment to the 2018 Amended and Restated...